Details of the Drug
General Information of Drug (ID: DMOLR5W)
| Drug Name |
Yttrium (90Y) clivatuzumab tetraxetan
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Antibody
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Pancreatic cancer | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 2C10 | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||
References

